Major depressive disorder (MDD) is the second leading cause of years lived with disability worldwide, affecting 16 million adults in the United States each year.
1 Typically less than 50% of patients with MDD respond (≥50% reduction in depressive symptoms) to their initial antidepressant medication and even fewer achieve remission (symptoms return to the healthy range).
2 Clinicians must decide for each patient whether antidepressant treatment is likely to increase the chances of response and ideally remission, weighing the benefits against the undesirable outcomes, including adverse effect burden.
3